1. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS) Raza, Azra; Galili, Naomi; Mulford, Deborah; Smith, Scott; Brown, Gail; Steensma, David; Lyons, Roger; Boccia, Ralph; Sekeres, Mikkael; Garcia-Manero, Guillermo; Mesa, Ruben 2012 Articles MedicineOncology